If you have an account please sign in to continue
An account is a great way to keep track and manage your activity within our site.
If you have already entered your email address and created a password while completing a form within our site, it is likely you have an account. You should have received an email to confirm this.
Dialog Box
Support - Education - Advocacy - Research
CFStrong is designed to inform and educate young people and adults who either have or know someone with cystic fibrosis (CF). Learn about various topics through our broad range of articles, conversations and personal stories!
Find out more about what we do to support people living with CF and their families.
Cystic fibrosis (also called CF) is the most common, life-limiting genetic condition affecting Australians.
CF causes an abnormal build-up of thick and sticky mucus in the lungs, airways and digestive system. Treatment requires intensive daily physiotherapy to clear the lungs and airways, countless medications and frequent hospitalisations.
Find out more Get support
Learn more about CF so you can be confident in managing your child's condition.
During your teenage years, you start to take over more management of CF from your family.
Tools, information and advice to support you to live your life while managing CF.
When you care for someone living with CF, looking after yourself needs to be important part of the plan.
Every donation received and every dollar raised no matter how big or small, has the power to make a difference to the life of someone living with cystic fibrosis. All funds raised for Cystic Fibrosis Community Care help us to deliver support services and improve the lives of people living with CF, their families and carers.
Fundraise Donate
3,500 people are living with CF in Australia and 1 in 25 people carry the recessive CF gene change. Babies born today with CF can expect to live well into adulthood. There is no cure but advances in treatment and care are helping people to better manage their condition.
News
Approximately 300 families with children aged 2-5 who have at least one F508del mutation, are waiting for Trikafta. With the Pharmaceutical Benefits Advisory Committee meeting being held later this week, we hope a positive outcome will be reached.
Loxegen's nanoparticle gene therapy for cystic fibrosis (CF) has secured a significant $1.5 million grant from the Australian Government’s $230m Medical Research Future Fund (MRFF), with additional contributions pushing the total funding to over $3million
In Australia, as across the globe, the rising cost of living continues to be a pressing concern for many, significantly affecting those living with chronic conditions such as cystic fibrosis (CF).
Stephanie Quattromani, Head of Programs and Research at CFCC, recently attended the North American Cystic Fibrosis Conference (NACFC). Here she recaps the highlights from the conference and recent trends in research.
Please enter a valid email address